GlassScriptPhysician profile
Luanda P Grazette
NPI 1013223064
$19,163.77
in general payments reported to CMS, 2019-2025
24 companies · $757 in 2025
The $757 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $11.35 · 2021: $781 · 2022: $4,213 · 2023: $12K · 2024: $579 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,900 · Travel and Lodging: $3,682 · Food and Beverage: $2,862 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,900.00 |
| Travel and Lodging | $3,682.32 |
| Food and Beverage | $2,862.18 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $10,799.60 | 2019-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $4,833.32 | 2022-2023 | Optimizer |
| Boston Scientific Corporation | $783.28 | 2019-2025 | Sentinel, Watchman Access System, Watchman Flx |
| Medicure Pharma INC. | $615.02 | 2019 | |
| Abbott Laboratories | $482.64 | 2019-2023 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $249.02 | 2023-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $215.66 | 2019-2025 | |
| Abiomed | $214.29 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $213.37 | 2021-2023 | Lifevest |
| Alnylam Pharmaceuticals INC. | $159.66 | 2023-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $124.50 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $88.76 | 2023 | Brilinta |
| Pfizer INC. | $51.38 | 2025 | |
| Amgen INC. | $50.00 | 2019 | |
| Merck Sharp & Dohme LLC | $45.83 | 2025 | Verquvo, Capvaxive |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $42.12 | 2021 | |
| Philips North America LLC | $34.78 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Scpharmaceuticals INC. | $27.90 | 2023 | |
| Glaxosmithkline, LLC. | $27.47 | 2025 | Shingrix, Arexvy |
| Medtronic, INC. | $23.57 | 2023 | Hvad Pump Implant Kit |
| Ge Healthcare | $22.00 | 2025 | |
| Kestra Medical Technology Services, INC. | $21.13 | 2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $20.72 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $17.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luanda Grazette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.